VCYT
Veracyte, Inc.
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue
